Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
Objective: Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis. Materials and Methods: This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psor...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dow University of Health Sciences
2014-08-01
|
Series: | Journal of the Dow University of Health Sciences |
Subjects: | |
Online Access: | http://www.jduhs.com/index.php/jduhs/article/view/116 |
id |
doaj-e5b2f04b0dc24a06991e668c593747a8 |
---|---|
record_format |
Article |
spelling |
doaj-e5b2f04b0dc24a06991e668c593747a82020-11-25T03:29:08ZengDow University of Health SciencesJournal of the Dow University of Health Sciences1995-21982410-21802014-08-01825961116Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type PsoriasisSana Imran0Moosa Khan1Mohammad Sair2Sarwat Jahan3Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan.Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan.Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan.Department of Pharmacology and Therapeutics, Basic Medical Science Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan.Objective: Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis. Materials and Methods: This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psoriatic (mild and moderate) patients were included in the study and they were divided into two groups, A and B; 40 patients in each group. The patients of group A were treated by Betamethasone valerate (0.1%) and the patients of group B were treated by Calcipotriol (0.005%). To observe any significant changes, the PASI parameter was applied at the end of study period. Results: Psoriasis severity improvement was monitored by Psoriasis Area Severity Index (PASI). As comparedto day 0, the mean PASI score changes in both treated groups i.e group A (Betamethasone valerate) and groupB (Calcipotriol) was highly significant at day 90 but the changes in mean PASI score was more marked ingroup B. In mild psoriasis, Calcipotriol causes 71.61% improvement in PASI score whereas Betamethasonevalerate causes 63.2% improvement. In moderate psoriasis, Calcipotriol causes 69.21% improvement in PASI score whereas Betamethasone valerate causes 60.44% improvement. Conclusion: Topical Calcipotriol was more effective in improvement of mild and moderate plaque psoriasis as compared to Betamethasone valerate in local population.http://www.jduhs.com/index.php/jduhs/article/view/116calcipotriolbetamethasone valerateplaque psoriasispsoriasis area severity index (pasi) parameter |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sana Imran Moosa Khan Mohammad Sair Sarwat Jahan |
spellingShingle |
Sana Imran Moosa Khan Mohammad Sair Sarwat Jahan Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis Journal of the Dow University of Health Sciences calcipotriol betamethasone valerate plaque psoriasis psoriasis area severity index (pasi) parameter |
author_facet |
Sana Imran Moosa Khan Mohammad Sair Sarwat Jahan |
author_sort |
Sana Imran |
title |
Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis |
title_short |
Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis |
title_full |
Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis |
title_fullStr |
Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis |
title_full_unstemmed |
Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis |
title_sort |
comparative role of topical betamethasone valerate with topical calcipotriol in mild and moderate plaque type psoriasis |
publisher |
Dow University of Health Sciences |
series |
Journal of the Dow University of Health Sciences |
issn |
1995-2198 2410-2180 |
publishDate |
2014-08-01 |
description |
Objective:
Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis.
Materials and Methods:
This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psoriatic (mild and moderate) patients were included in the study and they were divided into two groups, A and B; 40 patients in each group. The patients of group A were treated by Betamethasone valerate (0.1%) and the patients of group B were treated by Calcipotriol (0.005%). To observe any significant changes, the PASI parameter was applied at the end of study period.
Results:
Psoriasis severity improvement was monitored by Psoriasis Area Severity Index (PASI). As comparedto day 0, the mean PASI score changes in both treated groups i.e group A (Betamethasone valerate) and groupB (Calcipotriol) was highly significant at day 90 but the changes in mean PASI score was more marked ingroup B. In mild psoriasis, Calcipotriol causes 71.61% improvement in PASI score whereas Betamethasonevalerate causes 63.2% improvement. In moderate psoriasis, Calcipotriol causes 69.21% improvement in PASI score whereas Betamethasone valerate causes 60.44% improvement.
Conclusion:
Topical Calcipotriol was more effective in improvement of mild and moderate plaque psoriasis as compared to Betamethasone valerate in local population. |
topic |
calcipotriol betamethasone valerate plaque psoriasis psoriasis area severity index (pasi) parameter |
url |
http://www.jduhs.com/index.php/jduhs/article/view/116 |
work_keys_str_mv |
AT sanaimran comparativeroleoftopicalbetamethasonevaleratewithtopicalcalcipotriolinmildandmoderateplaquetypepsoriasis AT moosakhan comparativeroleoftopicalbetamethasonevaleratewithtopicalcalcipotriolinmildandmoderateplaquetypepsoriasis AT mohammadsair comparativeroleoftopicalbetamethasonevaleratewithtopicalcalcipotriolinmildandmoderateplaquetypepsoriasis AT sarwatjahan comparativeroleoftopicalbetamethasonevaleratewithtopicalcalcipotriolinmildandmoderateplaquetypepsoriasis |
_version_ |
1724580430896693248 |